ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Nastech Completes Enrollment Of Phase 2 Clinical Trial Of PYY3-36 Nasal Spray To Treat Obesity
Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced the completion of enrollment for its
Phase 2 clinical trial of PYY3-36 Nasal Spray to treat obesity. The Company
enrolled 551 obese patients at multiple clinical sites in the United States
for a six-month, randomized, placebo-controlled dose ranging study. The
study is designed to evaluate three different doses of PYY3-36 Nasal Spray
compared to placebo and sibutramine (Meridia(R)), a commercially available
oral weight loss drug, with the primary endpoint being weight loss.
"We are pleased with the rapid enrollment of 551 patients into the
Phase 2 study to evaluate PYY3-36 nasal spray as a novel treatment for
obesity. The fact that we exceeded our enrollment target of 510 patients is
an indication of the unmet need for an effective obesity therapeutic,"
stated Gordon Brandt, M.D., President of Nastech. "The dramatic rise in
obesity globally requires safe and effective treatment options for the
hundreds of millions of people whose lives are impacted by this condition.
If successful, PYY Nasal Spray would offer a patient-friendly product to
promote weight loss."
About PYY
Peptide YY is a naturally occurring hormone that is believed to
function as a physiologic inhibitor of food intake. PYY is released into
the blood stream from specialized endocrine cells (L-cells) in the gut
after a meal and is believed to trigger the feeling of satiety, or
fullness. Because PYY is a peptide, initial studies focused on PYY delivery
by injection. Utilizing its proprietary drug delivery technology, Nastech
developed the nasal spray formulation of PYY as a unique, non-invasive
treatment option for obesity.
About Nastech
Nastech is a biopharmaceutical company developing innovative products
based on proprietary molecular biology-based drug delivery technologies.
Nastech is creating technologies that enable the delivery of peptide and
protein therapeutics without the requirement of an injection, which is
currently the most common form of administration for this class of drugs.
Nastech has also established a wholly-owned subsidiary, MDRNA, Inc., to
focus on developing RNA-based technologies and therapeutics. MDRNA is
harnessing the power of RNA interference, a cellular mechanism that can
turn off the production of a specific protein through use of small
interfering RNAs (siRNAs), to develop a new class of therapeutics by
identifying key protein targets, designing the siRNAs that will turn off
the production of the targeted proteins, and creating a formulation for the
delivery of the therapeutics. Nastech and its collaboration partners are
developing products for multiple therapeutic areas including osteoporosis,
obesity, diabetes, autism, respiratory diseases and inflammatory
conditions. For additional information about Nastech please visit
http://www.nastech.com.
Nastech Forward Looking Statements
Statements made in this press release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to certain
risks and uncertainties and involve factors that may cause actual results
to differ materially from those projected or suggested. Factors that could
cause actual results to differ materially from those in forward-looking
statements include, but are not limited to: (i) the ability of Nastech or a
subsidiary to obtain additional funding; (ii) the ability of Nastech or a
subsidiary to attract and/or maintain manufacturing, research, development
and commercialization partners; (iii) the ability of Nastech, a subsidiary
and/or a partner to successfully complete product research and development,
including preclinical and clinical studies and commercialization; (iv) the
ability of Nastech, a subsidiary and/or a partner to obtain required
governmental approvals; and (v) the ability of Nastech, a subsidiary and/or
a partner to develop and commercialize products that can compete favorably
with those of competitors. Additional factors that could cause actual
results to differ materially from those projected or suggested in any
forward-looking statements are contained in Nastech's most recent periodic
reports on Form 10-K and Form 10-Q that are filed with the Securities and
Exchange Commission. Nastech assumes no obligation to update and supplement
forward-looking statements because of subsequent events.
Nastech Pharmaceutical Company Inc.
http://www.nastech.com
Nastech completeaza de înscriere Din studiile clinice de fazã 2 Din PYY3-36 nazale pulverizare pentru a trata Obezitate - Nastech Completes Enrollment Of Phase 2 Clinical Trial Of PYY3-36 Nasal Spray To Treat Obesity - articole medicale engleza - startsanatate